Invex Therapeutics Past Earnings Performance
Past criteria checks 0/6
Invex Therapeutics's earnings have been declining at an average annual rate of -19.7%, while the Pharmaceuticals industry saw earnings growing at 35.1% annually. Revenues have been growing at an average rate of 70% per year.
Key information
-19.7%
Earnings growth rate
-12.9%
EPS growth rate
| Pharmaceuticals Industry Growth | 31.2% |
| Revenue growth rate | 70.0% |
| Return on equity | -28.9% |
| Net Margin | -135.4% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Invex Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 1 | -2 | 1 | 2 |
| 31 Mar 24 | 1 | -4 | 1 | 4 |
| 31 Dec 23 | 0 | -6 | 2 | 6 |
| 30 Sep 23 | 0 | -7 | 2 | 6 |
| 30 Jun 23 | 0 | -8 | 2 | 7 |
| 31 Mar 23 | 1 | -7 | 1 | 6 |
| 31 Dec 22 | 1 | -6 | 1 | 5 |
| 30 Sep 22 | 0 | -5 | 1 | 4 |
| 30 Jun 22 | 0 | -4 | 1 | 3 |
| 31 Mar 22 | 0 | -3 | 1 | 2 |
| 31 Dec 21 | 0 | -3 | 1 | 2 |
| 30 Sep 21 | 0 | -3 | 1 | 1 |
| 30 Jun 21 | 0 | -2 | 1 | 1 |
| 31 Mar 21 | 0 | -3 | 2 | 1 |
| 31 Dec 20 | 0 | -3 | 2 | 1 |
| 30 Sep 20 | 0 | -3 | 2 | 1 |
| 30 Jun 20 | 0 | -3 | 2 | 2 |
Quality Earnings: IXC is currently unprofitable.
Growing Profit Margin: IXC is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: IXC is unprofitable, and losses have increased over the past 5 years at a rate of 19.7% per year.
Accelerating Growth: Unable to compare IXC's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: IXC is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (26.6%).
Return on Equity
High ROE: IXC has a negative Return on Equity (-28.86%), as it is currently unprofitable.